Advanced non-small cell lunch cancer study

Participants will be randomly assigned to receive chemotherapy with cetuximab, or chemotherapy without cetuximab. There are 4 groups in this study. Those assigned to Group 1 will receive six 3-week cycles of chemotherapy with paclitaxel, carboplatin and bevacizumab. All of the drugs are given through an IV (through the vein) once every 3 weeks. Those assigned to Group 2 will receive six 3-week cycles of chemotherapy with paclitaxel and carboplatin. As in Group 1, all of the drugs are given through an IV once every 3 weeks. Those assigned to Group 3 will receive six 3-week cycles of chemotherapy with cetuximab, paclitaxel, carboplatin and bevacizumab. As with the other two groups, all of the drugs are given through a vein. With the exception of cetuximab, which is given once a week, all of the other drugs used in Group 3 are given once every 3 weeks. Those assigned to Group 4 will receive six 3-week cycles of chemotherapy with cetuximab, paclitaxel and carboplatin. Cetuximab will be given once per week, and the other drugs will be given once every 3 weeks. Tissue specimens from the biopsy or surgery used to diagnose their cancer plus blood specimens from pre-treatment, at Week 7, and when they stop treatment will be sent to a laboratory to see if the researchers can predict which patients should receive cetuximab as part of their treatment in the future. The blood specimens will be taken at the same time that blood is taken for laboratory tests.